Alberta Enterprise Corporation announced today that it has made an investment into Amplitude Ventures‘ USD $192-million Fund II.
The USD $7.5 million investment aims to provide early-stage health and life science startups in Alberta with continued access to Amplitude’s specialized expertise and funding in precision medicine.
Amplitude Ventures is a full-stack venture capital firm focused on investing in precision medicine at the intersection of biology and AI.
Since 2019, the firm has invested in entrepreneurs creating and building precision health companies including Repare Therapeutics, Abdera, Valence (acquired by Recursion) and Edmonton’s DrugBank which has developed the world’s most comprehensive drug knowledge platform. AEC invested in Amplitude’s first fund and is returning as an investor in Fund II.
“Alberta life science startups require access to capital and expertise from specialized life science investors in order to scale,” commented Kristina Williams, CEO, Alberta Enterprise Corporation.
“Amplitude contributes deep expertise to help Alberta entrepreneurs building new precision medicine companies which can drive meaningful outcomes in human health and transform the future of healthcare.”
Amplitude built an early connection to Alberta in 2022 via a strategic alliance with Edmonton-based AltaML bringing together the AI and ML expertise of AltaML and the life science company building expertise of Amplitude.
With the final close of Fund II, Amplitude announced that it is establishing a full-time presence in Alberta with the hire of Nadia Lachman, in Calgary. Lachman, a University of Calgary alum, brings a background in health science and biomedical technology and well as venture capital investment experience.
Leave a Reply